Prophase Labs Stock Performance
| PRPH Stock | USD 0.42 0.03 6.04% |
The company holds a Beta of -2.49, which implies a somewhat significant risk relative to the market. As returns on the market increase, returns on owning ProPhase Labs are expected to decrease by larger amounts. On the other hand, during market turmoil, ProPhase Labs is expected to outperform it. At this point, ProPhase Labs has a negative expected return of -2.11%. Please make sure to check ProPhase Labs' jensen alpha, kurtosis, as well as the relationship between the Kurtosis and price action indicator , to decide if ProPhase Labs performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days ProPhase Labs has generated negative risk-adjusted returns adding no value to investors with long positions. Despite weak performance in the last few months, the Stock's basic indicators remain fairly strong which may send shares a bit higher in March 2025. The recent confusion may also be a sign of long-lasting up-swing for the firm traders. ...more
Last Split Factor 2:1 | Dividend Date 2022-06-03 | Ex Dividend Date 2022-05-24 | Last Split Date 1997-01-23 |
1 | ProPhase Labs announces proposed public offering of common stock | 11/07/2024 |
2 | Amneal Pharmaceuticals Surpasses Q3 Earnings and Revenue Estimates | 11/08/2024 |
3 | ProPhase Labs files for mixed shelf offering | 11/12/2024 |
4 | ProPhase Labs, Inc. Reports Q3 Loss, Tops Revenue Estimates | 11/13/2024 |
5 | Diamond Equity Research Releases Update Note on ProPhase Labs Inc. | 11/18/2024 |
6 | ProPhase Labs Inc Q3 2024 Earnings Call Highlights Strategic Launches and Financial ... | 11/19/2024 |
7 | ProPhase Labs secures private equity backing, nears lozenge deal, and plans cost-cutting measures | 12/11/2024 |
8 | ProPhase Labs stock hits 52-week low at 0.64 amid sharp decline - Investing.com India | 12/20/2024 |
9 | ProPhase Labs stock hits 52-week low at 0.41 amid sharp decline - MSN | 01/29/2025 |
| Begin Period Cash Flow | 9.1 M | |
| Free Cash Flow | -14.5 M |
ProPhase |
ProPhase Labs Relative Risk vs. Return Landscape
If you would invest 214.00 in ProPhase Labs on November 1, 2024 and sell it today you would lose (169.00) from holding ProPhase Labs or give up 78.97% of portfolio value over 90 days. ProPhase Labs is currently does not generate positive expected returns and assumes 9.0923% risk (volatility on return distribution) over the 90 days horizon. In different words, 81% of stocks are less volatile than ProPhase, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
ProPhase Labs Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for ProPhase Labs' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as ProPhase Labs, and traders can use it to determine the average amount a ProPhase Labs' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.2322
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | PRPH |
Estimated Market Risk
| 9.09 actual daily | 81 81% of assets are less volatile |
Expected Return
| -2.11 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.23 actual daily | 0 Most of other assets perform better |
Based on monthly moving average ProPhase Labs is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of ProPhase Labs by adding ProPhase Labs to a well-diversified portfolio.
ProPhase Labs Fundamentals Growth
ProPhase Stock prices reflect investors' perceptions of the future prospects and financial health of ProPhase Labs, and ProPhase Labs fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on ProPhase Stock performance.
| Return On Equity | -0.51 | ||||
| Return On Asset | -0.23 | ||||
| Profit Margin | (1.46) % | ||||
| Operating Margin | (3.16) % | ||||
| Current Valuation | 40.07 M | ||||
| Shares Outstanding | 23.87 M | ||||
| Price To Earning | 6.59 X | ||||
| Price To Book | 0.29 X | ||||
| Price To Sales | 0.60 X | ||||
| Revenue | 44.38 M | ||||
| Gross Profit | (1.64 M) | ||||
| EBITDA | (14.83 M) | ||||
| Net Income | (16.78 M) | ||||
| Cash And Equivalents | 27.5 M | ||||
| Cash Per Share | 1.72 X | ||||
| Total Debt | 21.38 M | ||||
| Debt To Equity | 0.19 % | ||||
| Current Ratio | 4.20 X | ||||
| Book Value Per Share | 2.74 X | ||||
| Cash Flow From Operations | (11.35 M) | ||||
| Earnings Per Share | (1.53) X | ||||
| Market Capitalization | 10.7 M | ||||
| Total Asset | 91.93 M | ||||
| Retained Earnings | (5.03 M) | ||||
| Working Capital | 26.73 M | ||||
| Current Asset | 9.73 M | ||||
| Current Liabilities | 6.25 M | ||||
About ProPhase Labs Performance
By evaluating ProPhase Labs' fundamental ratios, stakeholders can gain valuable insights into ProPhase Labs' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if ProPhase Labs has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if ProPhase Labs has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 57.28 | 54.42 | |
| Return On Tangible Assets | (0.20) | (0.19) | |
| Return On Capital Employed | (0.35) | (0.33) | |
| Return On Assets | (0.18) | (0.16) | |
| Return On Equity | (0.31) | (0.29) |
Things to note about ProPhase Labs performance evaluation
Checking the ongoing alerts about ProPhase Labs for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for ProPhase Labs help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| ProPhase Labs generated a negative expected return over the last 90 days | |
| ProPhase Labs has high historical volatility and very poor performance | |
| ProPhase Labs has some characteristics of a very speculative penny stock | |
| The company reported the previous year's revenue of 44.38 M. Net Loss for the year was (16.78 M) with loss before overhead, payroll, taxes, and interest of (1.64 M). | |
| ProPhase Labs currently holds about 27.5 M in cash with (11.35 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.72, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 14.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from news.google.com: ProPhase Labs stock hits 52-week low at 0.41 amid sharp decline - MSN |
- Analyzing ProPhase Labs' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether ProPhase Labs' stock is overvalued or undervalued compared to its peers.
- Examining ProPhase Labs' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating ProPhase Labs' management team can have a significant impact on its success or failure. Reviewing the track record and experience of ProPhase Labs' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of ProPhase Labs' stock. These opinions can provide insight into ProPhase Labs' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for ProPhase Stock analysis
When running ProPhase Labs' price analysis, check to measure ProPhase Labs' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ProPhase Labs is operating at the current time. Most of ProPhase Labs' value examination focuses on studying past and present price action to predict the probability of ProPhase Labs' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ProPhase Labs' price. Additionally, you may evaluate how the addition of ProPhase Labs to your portfolios can decrease your overall portfolio volatility.
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital |